An assessment of the prescribing preferences of Irish dermatology consultants for the treatment of severe psoriasis in the setting of a cancer diagnosis.
[AIM] We aimed to investigate the systemic and biologic agent choices of dermatologists in Ireland for those patients with psoriasis and a cancer diagnosis.
APA
Bowe S, Murphy M, et al. (2025). An assessment of the prescribing preferences of Irish dermatology consultants for the treatment of severe psoriasis in the setting of a cancer diagnosis.. Irish journal of medical science, 194(6), 2183-2190. https://doi.org/10.1007/s11845-025-04113-0
MLA
Bowe S, et al.. "An assessment of the prescribing preferences of Irish dermatology consultants for the treatment of severe psoriasis in the setting of a cancer diagnosis.." Irish journal of medical science, vol. 194, no. 6, 2025, pp. 2183-2190.
PMID
41028666
Abstract
[AIM] We aimed to investigate the systemic and biologic agent choices of dermatologists in Ireland for those patients with psoriasis and a cancer diagnosis.
[METHODS] An electronic questionnaire was circulated to the Irish Association of Dermatology members using the survey platform, Jotform, between December 2023-June 2025.
[RESULTS] In total there were 27 responses. Methotrexate was selected most commonly for all scenarios > 5 years remission. In all clinical scenarios, fumaric acid esters were the least frequently selected agents. In general, tumour necrosis factor-alpha inhibitors were the next least commonly selected. Apremilast was selected most commonly for a current malignancy of stage 1 breast cancer (26%), lymphoma (22%) and metastatic RCC (30%).
[CONCLUSION] In general, systemic and biologic agents are used by Irish dermatologists in the setting of psoriasis and cancer.
[METHODS] An electronic questionnaire was circulated to the Irish Association of Dermatology members using the survey platform, Jotform, between December 2023-June 2025.
[RESULTS] In total there were 27 responses. Methotrexate was selected most commonly for all scenarios > 5 years remission. In all clinical scenarios, fumaric acid esters were the least frequently selected agents. In general, tumour necrosis factor-alpha inhibitors were the next least commonly selected. Apremilast was selected most commonly for a current malignancy of stage 1 breast cancer (26%), lymphoma (22%) and metastatic RCC (30%).
[CONCLUSION] In general, systemic and biologic agents are used by Irish dermatologists in the setting of psoriasis and cancer.
MeSH Terms
Humans; Psoriasis; Ireland; Practice Patterns, Physicians'; Neoplasms; Surveys and Questionnaires; Methotrexate; Female; Dermatologists; Male; Dermatologic Agents; Consultants; Dermatology; Thalidomide